UCB, Inc.
37 drugs in NADAC|0 Generic,37 Brand
UCB, Inc. lists 37 NDCs in the CMS NADAC file (0 generic, 37 brand), at an average NADAC of $1006.52 per unit, with a week-over-week move of -0.0% across products that moved. The firm's full portfolio, pricing trend are listed below.
Total Drugs
37
0G / 37B
Avg Price / Unit
$1006.5244
$1.92 – $8112.59
Avg 7d Change
-0.01%
Across 25 drugs with changes
7d Activity
of 37 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Keep following this manufacturer
These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.
Lead market
brivaracetam market
See the molecule this manufacturer shows up in most often and compare it against competing suppliers.
Lead class
Nonergot Dopamine Agonist therapeutic class
Review the broader class where UCB, Inc. has the strongest current portfolio footprint.
Trend hub
Portfolio trend view
Jump to the trend hub to compare this manufacturer against the rest of the market on weekly price movement.
Guide
NADAC pricing primer
Use the explainer for context on the benchmark this manufacturer is being compared against.
Frequently Asked Questions
How many drugs does UCB, Inc. make?
UCB, Inc. lists 37 NDCs in the CMS NADAC file — 0 generic and 37 brand products.
What is the average price of UCB, Inc. drugs?
The average NADAC across UCB, Inc.'s portfolio is $1006.5244 per unit, ranging from $1.9189 to $8112.5853.
What types of drugs does UCB, Inc. make?
UCB, Inc. makes drugs across 3 FDA pharmacologic classes. The most common by NDC count are Nonergot Dopamine Agonist (6), Tumor Necrosis Factor Blocker (2), Benzodiazepine (1).
Has UCB, Inc. had any drug recalls?
No FDA enforcement recalls are matched to UCB, Inc. in the openFDA feed.
How has UCB, Inc.'s pricing changed recently?
Over the past 7 days, 11 UCB, Inc. products rose and 14 fell, with a portfolio-wide average change of -0.0%.